By Uduak Grace Thomas

NuMedii, a Stanford University spinoff, hopes to make its bread and butter by partnering with traditional and specialty pharmaceutical companies to identify new indications for existing medicines.

The company's business relies on a platform, called New Indications Discovery, based on bioinformatics tools that were developed at Stanford.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.